Open AccessThe Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease
Author(s) -
H. Bryan Brewer
Publication year - 2011
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2010-0163
Subject(s) - medicine , cholesterylester transfer protein , lipoprotein , cholesterol , reverse cholesterol transport , disease , clinical trial , high density lipoprotein , statin , antithrombotic , pharmacology , bioinformatics , endocrinology , biology
Statin treatment of cardiovascular patients reduces clinical events by 25 to 45%. High-density lipoprotein (HDL) has been proposed as a therapeutic target to further reduce this residual cardiovascular risk.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom